BioSpace News Archive

Ceapro Inc. announced operational highlights and financial results for the fourth quarter and full year ended December 31, 2023.

GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Portrait VSM vital signs monitor that can provide clinicians with an accurate view of patient vital signs to support timely clinical decisions.

NanoAi Technologies, a company pioneering advancements in threat detection, today unveiled the NanoAi Technologies analyzer, a groundbreaking device designed to revolutionize security and safety measures across various sectors.

PANTHERx® Rare today announced it was selected by X4 Pharmaceuticals, Inc. for the distribution of XOLREMDI™ (mavorixafor), recently approved by the U.S. Food and Drug Administration (FDA) and the first FDA-approved therapy specifically indicated for use in patients 12 years of age and older with warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome.

Kedrion Biopharma Inc. announced today that plasminogen deficiency type 1 (PLGD-1) patients in the U.S. now have access to RYPLAZIM® (plasminogen, human-tvmh).

Healthcare providers are a vital resource for autistic adolescents and their families as they prepare for the transition to adulthood, which may include learning to drive, according to a new study from researchers at Children’s Hospital of Philadelphia, recently published in the Journal of Autism and Developmental Disorders.

IRLAB Therapeutics, a company discovering and developing novel treatments for Parkinson’s disease, announced that the Annual Report for 2023 is published on the company’s website.

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2024 financial results on Wednesday, May 8, 2024, after the close of the market.

The global influenza vaccine market was valued at US$ 8.78 billion in 2023. The global market is projected to hit the market valuation of US$ 22.71 billion by 2032, growing at a CAGR of 11.07% during the forecast period from 2024 to 2032.

C4 Therapeutics, Inc. announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 146,880 shares of the Company’s common stock to one new employee, with the grant made on April 29, 2024.